Nugent, Allison C.
Ballard, Elizabeth D.
Park, Lawrence T.
Zarate, Carlos A. Jr
Funding for this research was provided by:
National Institute of Mental Health (ZIA MH002927)
Article History
Received: 25 March 2019
Accepted: 20 September 2019
First Online: 1 November 2019
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: Dr. Zarate is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation; as a co-inventor on a patent for the use of (2<i>R</i>,6<i>R</i>)-hydroxynorketamine, (<i>S</i>)-dehydronorketamine, and other stereoisomeric dehydro and hydroxylated metabolites of (<i>R,S</i>)-ketamine metabolites in the treatment of depression and neuropathic pain; and as a co-inventor on a patent application for the use of (2<i>R</i>,6<i>R</i>)-hydroxynorketamine and (2<i>S</i>,6<i>S</i>)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders. He has assigned his patent rights to the U.S. government but will share a percentage of any royalties that may be received by the government. All other authors have no conflict of interest to disclose, financial or otherwise.